Do analysts rate NDRA or IINN?

ENDRA Life Sciences currently has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, NDRA or IINN?

ENDRA Life Sciences has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$6.38 N/A Inspira Technologies OXY B.H.N. $289K 109.46 -$13.22M N/A N/A

Is NDRA or IINN more profitable?

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -246.34% -150.81% Inspira Technologies OXY B.H.N. N/A N/A N/A

Do analysts prefer QTEX or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, QTEX or NDRA?

ENDRA Life Sciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $290K 102.35 -$13.22M N/A N/A ENDRA Life Sciences N/A N/A -$7.03M -$6.38 N/A

Is QTEX or NDRA more profitable?

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Inspira Technologies OXY B.H.N. N/A N/A N/A ENDRA Life Sciences N/A -246.34% -150.81%

Is NDRA or FEMY more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Femasys' return on equity of -225.97% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -246.34% -150.81% Femasys -534.36% -225.97% -74.68%

Does the media refer more to NDRA or FEMY?

In the previous week, Femasys had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for Femasys and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.40 beat Femasys' score of 0.32 indicating that ENDRA Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ENDRA Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Femasys 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, BEAT or NDRA?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartBeam N/A N/A -$21.01M -$0.51 N/A ENDRA Life Sciences N/A N/A -$7.03M -$6.38 N/A

Is BEAT or NDRA more profitable?

ENDRA Life Sciences' return on equity of -246.34% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% ENDRA Life Sciences N/A -246.34% -150.81%

Do analysts recommend PETV or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PETV or NDRA more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. ENDRA Life Sciences' return on equity of -246.34% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% ENDRA Life Sciences N/A -246.34% -150.81%

Does the media prefer PETV or NDRA?

In the previous week, PetVivo had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for PetVivo and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.40 beat PetVivo's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ENDRA Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ENDRA Life Sciences (NDRA) Competitors

$5.83 -0.08 (-1.35%)

Closing price 03:57 PM Eastern

Extended Trading

$5.88 +0.05 (+0.86%)

As of 07:30 PM Eastern

Compare

NDRA vs. IINN, QTEX, FEMY, BEAT, and PETV

Should you buy ENDRA Life Sciences stock or one of its competitors? ENDRA Life Sciences's main competitors and comparable companies include Inspira Technologies OXY B.H.N. (IINN), Inspira Technologies OXY B.H.N. (QTEX), Femasys (FEMY), HeartBeam (BEAT), and PetVivo (PETV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

ENDRA Life Sciences (NASDAQ:NDRA) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

ENDRA Life Sciences has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A
Inspira Technologies OXY B.H.N.	$289K	109.46	-$13.22M	N/A	N/A

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-246.34%	-150.81%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Inspira Technologies OXY B.H.N.. ENDRA Life Sciences' average media sentiment score of 1.40 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
ENDRA Life Sciences	Positive
Inspira Technologies OXY B.H.N.	Neutral

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ENDRA Life Sciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

ENDRA Life Sciences currently has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ENDRA Life Sciences and Inspira Technologies OXY B.H.N. tied by winning 6 of the 12 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Inspira Technologies OXY B.H.N. has a beta of 4.24, suggesting that its share price is 324% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

ENDRA Life Sciences has lower revenue, but higher earnings than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$290K	102.35	-$13.22M	N/A	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Company	Overall Sentiment
Inspira Technologies OXY B.H.N.	Neutral
ENDRA Life Sciences	Positive

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Inspira Technologies OXY B.H.N. and ENDRA Life Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Femasys?

ENDRA Life Sciences (NASDAQ:NDRA) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, Femasys had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for Femasys and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.40 beat Femasys' score of 0.32 indicating that ENDRA Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Femasys	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ENDRA Life Sciences has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Femasys' return on equity of -225.97% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-246.34%	-150.81%
Femasys	-534.36%	-225.97%	-74.68%

ENDRA Life Sciences has higher earnings, but lower revenue than Femasys. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A
Femasys	$2.29M	10.36	-$18.63M	-$3.53	N/A

ENDRA Life Sciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Femasys has a beta of -2.07, meaning that its share price is 307% less volatile than the broader market.

ENDRA Life Sciences presently has a consensus price target of $25.00, suggesting a potential upside of 328.82%. Femasys has a consensus price target of $50.00, suggesting a potential upside of 1,666.78%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 7.8% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Femasys beats ENDRA Life Sciences on 10 of the 15 factors compared between the two stocks.

How does ENDRA Life Sciences compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, ENDRA Life Sciences had 1 more articles in the media than HeartBeam. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for HeartBeam. ENDRA Life Sciences' average media sentiment score of 1.40 beat HeartBeam's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartBeam	Neutral
ENDRA Life Sciences	Positive

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 853.97%. ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given HeartBeam's stronger consensus rating and higher possible upside, research analysts plainly believe HeartBeam is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ENDRA Life Sciences' return on equity of -246.34% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

HeartBeam has a beta of -0.8, indicating that its share price is 180% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

Summary

HeartBeam beats ENDRA Life Sciences on 8 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to PetVivo?

PetVivo (NASDAQ:PETV) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

24.5% of PetVivo shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 10.8% of PetVivo shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ENDRA Life Sciences has lower revenue, but higher earnings than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	23.58	-$10.95M	-$0.34	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

In the previous week, PetVivo had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for PetVivo and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.40 beat PetVivo's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ENDRA Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PetVivo has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 328.82%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ENDRA Life Sciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. ENDRA Life Sciences' return on equity of -246.34% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Summary

ENDRA Life Sciences beats PetVivo on 9 of the 15 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NDRA vs. The Competition

Export

Metric	ENDRA Life Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.86M	$5.58B	$7.23B	$12.88B
Dividend Yield	N/A	1.78%	2.55%	9.95%
P/E Ratio	-0.91	24.82	271.78	25.29
Price / Sales	N/A	71.76	709.75	112.40
Price / Cash	N/A	32.78	77.55	52.32
Price / Book	3.04	6.00	10.63	6.26
Net Income	-$7.03M	$150.94M	$3.48B	$357.86M
7 Day Performance	-9.75%	-2.43%	-1.38%	-0.39%
1 Month Performance	27.57%	-1.13%	2.17%	-1.28%
1 Year Performance	40.14%	7.70%	20.74%	11.50%

ENDRA Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NDRA ENDRA Life Sciences	2.9158 of 5 stars	$5.83 -1.4%	$25.00 +328.8%	+41.7%	$8.86M	N/A	N/A	20	Gap Down
IINN Inspira Technologies OXY B.H.N.	N/A	$0.83 -0.8%	N/A	-30.5%	$29.74M	$289K	N/A	20	High Trading Volume
QTEX Inspira Technologies OXY B.H.N.	0.1978 of 5 stars	$0.80 -3.5%	N/A	N/A	$29.74M	$290K	N/A	20
FEMY Femasys	3.2888 of 5 stars	$3.26 -5.0%	$50.00 +1,433.7%	-65.2%	$28.73M	$2.29M	N/A	30	News Coverage
BEAT HeartBeam	1.792 of 5 stars	$0.45 -3.3%	$4.00 +779.7%	-67.5%	$26.48M	N/A	N/A	1,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. IINN, QTEX, FEMY, BEAT, and PETV

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

Summary

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

Summary

How does ENDRA Life Sciences compare to Femasys?

Summary

How does ENDRA Life Sciences compare to HeartBeam?

Summary

How does ENDRA Life Sciences compare to PetVivo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. IINN, QTEX, FEMY, BEAT, and PETV

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

Which has stronger earnings and valuation, NDRA or IINN?

Is NDRA or IINN more profitable?

Does the media favor NDRA or IINN?

Do insiders and institutionals hold more shares of NDRA or IINN?

Which has more volatility and risk, NDRA or IINN?

Do analysts rate NDRA or IINN?

Summary

How does ENDRA Life Sciences compare to Inspira Technologies OXY B.H.N.?

Do analysts prefer QTEX or NDRA?

Which has more risk and volatility, QTEX or NDRA?

Which has stronger valuation & earnings, QTEX or NDRA?

Is QTEX or NDRA more profitable?

Does the media favor QTEX or NDRA?

Do insiders & institutionals have more ownership in QTEX or NDRA?

Summary

How does ENDRA Life Sciences compare to Femasys?

Does the media refer more to NDRA or FEMY?

Is NDRA or FEMY more profitable?

Which has stronger earnings and valuation, NDRA or FEMY?

Which has more volatility and risk, NDRA or FEMY?

Do analysts recommend NDRA or FEMY?

Do insiders & institutionals have more ownership in NDRA or FEMY?

Summary

How does ENDRA Life Sciences compare to HeartBeam?

Does the media favor BEAT or NDRA?

Do insiders and institutionals hold more shares of BEAT or NDRA?

Do analysts prefer BEAT or NDRA?

Is BEAT or NDRA more profitable?

Which has more volatility & risk, BEAT or NDRA?

Which has stronger earnings and valuation, BEAT or NDRA?

Summary

How does ENDRA Life Sciences compare to PetVivo?

Do institutionals and insiders have more ownership in PETV or NDRA?

Which has preferable valuation and earnings, PETV or NDRA?

Does the media prefer PETV or NDRA?

Which has more risk and volatility, PETV or NDRA?

Do analysts recommend PETV or NDRA?

Is PETV or NDRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools